{"_links":{"self":[{"href":"/project/GID-TA10914"}]},"_embedded":{"nice.indev:provisional-schedule-list":{"_links":{"self":[{}]},"_embedded":{"nice.indev:provisional-schedule":[{"_links":{"self":[{}]},"ETag":null,"Column1":"Draft guidance: 1","Column2":"21 February 2023 - 14 March 2023","AdditionalInfoLabel":null,"AdditionalInfo":"1","Hidden":false},{"_links":{"self":[{}]},"ETag":null,"Column1":"Committee meeting: 2","Column2":"07 June 2023","AdditionalInfoLabel":"Meeting number","AdditionalInfo":"2","Hidden":false},{"_links":{"self":[{}]},"ETag":null,"Column1":"Expected publication","Column2":"23 August 2023","AdditionalInfoLabel":null,"AdditionalInfo":null,"Hidden":false}]},"ETag":null},"nice.indev:timeline-list":{"_links":{"self":[{}]},"_embedded":{"nice.indev:timeline":[{"_links":{"self":[{}]},"ETag":null,"Column1":"12 January 2023","Column2":"Committee meeting: 1","AdditionalInfoLabel":"Meeting number","AdditionalInfo":"1","Hidden":false},{"_links":{"self":[{}]},"ETag":null,"Column1":"25 March 2022","Column2":"Invitation to participate","AdditionalInfoLabel":null,"AdditionalInfo":null,"Hidden":false},{"_links":{"self":[{}]},"ETag":null,"Column1":"17 February 2022 - 10 March 2022","Column2":"Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators","AdditionalInfoLabel":null,"AdditionalInfo":null,"Hidden":false},{"_links":{"self":[{}]},"ETag":null,"Column1":"21 February 2022","Column2":"In progress. Draft guidance released","AdditionalInfoLabel":"Link text","AdditionalInfo":null,"Hidden":false},{"_links":{"self":[{}]},"ETag":null,"Column1":"26 November 2021","Column2":"Following a request received from the company, NICE will be undertaking an appraisal of Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma. This was originally terminated guidance TA634.\r\nThe appraisal is expected to start during January 2022 with a consultation on the draft scope. It is then anticipated that the final scope will be released along with an invitation to participate in the appraisal during mid-March 2022. The deadline for submissions is expected in approximately late May 2022.","AdditionalInfoLabel":null,"AdditionalInfo":null,"Hidden":false}]},"ETag":null},"nice.indev:process-homepage":{"_links":{"self":[{"href":"https://www.nice.org.uk/about/what-we-do/our-programmes/nice-guidance/nice-technology-appraisal-guidance/changes-to-health-technology-evaluation"},{}]},"ETag":null,"Description":"For further information on our processes and methods, please see our","LinkText":"CHTE processes and methods manual"},"nice.indev:project-team-list":{"_links":{"self":[{}]},"_embedded":{"nice.indev:project-team":{"_links":{"self":[{}]},"ETag":null,"Column1":"Project lead","Column2":"Jeremy Powell"}},"ETag":null},"nice.indev:email-enquiry-list":{"_links":{"self":[{}]},"_embedded":{"nice.indev:email-enquiry":{"_links":{"self":[{}]},"ETag":null,"Item":"TAteam2@nice.org.uk"}},"ETag":null},"nice.indev:consultee-list":{"_links":{"self":[{}]},"_embedded":{"nice.indev:consultee":[{"_links":{"self":[{}]},"ETag":null,"Column1":"Companies sponsors","Column2":"Janssen "},{"_links":{"self":[{}]},"ETag":null,"Column1":"Others","Column2":"Department of Health and Social Care"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Others","Column2":"NHS England"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Others","Column2":"Welsh Government"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Patient carer groups","Column2":"Blood Cancer UK"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Patient carer groups","Column2":"Myeloma UK"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Professional groups","Column2":"Association of Cancer Physicians"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Professional groups","Column2":"Cancer Research UK"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Professional groups","Column2":"Royal College of Physicians"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Professional groups","Column2":"Royal College of Radiologists "},{"_links":{"self":[{}]},"ETag":null,"Column1":"Professional groups","Column2":"UK Myeloma Forum "}]},"ETag":null},"nice.indev:commentator-list":{"_links":{"self":[{}]},"_embedded":{"nice.indev:commentator":[{"_links":{"self":[{}]},"ETag":null,"Column1":"Associated public health groups","Column2":"Public Health England"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Associated public health groups","Column2":"Public Health Wales "},{"_links":{"self":[{}]},"ETag":null,"Column1":"Comparator companies","Column2":"Accord Healthcare (bortezomib, lenalidomide, thalidomide) (not participating)"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Comparator companies","Column2":"Advanz pharma (dexamethasone)"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Comparator companies","Column2":"Aspen (dexamethasone) (not participating)"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Comparator companies","Column2":"Aspire (bortezomib, dexamethasone) (not participating)"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Comparator companies","Column2":"Bristol-Myers Squibb (lenalidomide)"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Comparator companies","Column2":"Celgene (thalidomide)"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Comparator companies","Column2":"Consilient health (dexamethasone) (not participating)"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Comparator companies","Column2":"Focus Pharmaceuticals (dexamethasone) (not participating)"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Comparator companies","Column2":"Hameln Pharmaceuticals (dexamethasone) (not participating)"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Comparator companies","Column2":"Hospira (dexamethasone) (not participating)"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Comparator companies","Column2":"Janssen (bortezomib) (not participating)"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Comparator companies","Column2":"Martindale pharma (dexamethasone) (not participating)"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Comparator companies","Column2":"Merck, Sharp and Dohme (dexamethasone) (not participating)"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Comparator companies","Column2":"Mylan (bortezomib) (not participating)"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Comparator companies","Column2":"Piramal Critical Care (lenalidomide) (not participating)"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Comparator companies","Column2":"Rosemont Pharmaceuticals (dexamethasone) (not participating)"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Comparator companies","Column2":"Sandoz (bortezomib) (not participating)"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Comparator companies","Column2":"Teva (dexamethasone) (not participating)"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Comparator companies","Column2":"Thornton & Ross (bortezomib) (not participating)"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Comparator companies","Column2":"Zentiva (bortezomib) (not participating)"},{"_links":{"self":[{}]},"ETag":null,"Column1":"General commentators","Column2":"All Wales Therapeutics and Toxicology Centre "},{"_links":{"self":[{}]},"ETag":null,"Column1":"General commentators","Column2":"British National Formulary"},{"_links":{"self":[{}]},"ETag":null,"Column1":"General commentators","Column2":"Department of Health, Social Services and Public Safety for Northern Ireland"},{"_links":{"self":[{}]},"ETag":null,"Column1":"General commentators","Column2":"Healthcare Improvement Scotland"},{"_links":{"self":[{}]},"ETag":null,"Column1":"General commentators","Column2":"Medicines and Healthcare Products Regulatory Agency "},{"_links":{"self":[{}]},"ETag":null,"Column1":"General commentators","Column2":"Welsh Health Specialised Services Committee"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Relevant research groups","Column2":"Institute of Cancer Research"}]},"ETag":null},"nice.indev:panel-list":{"_links":{"self":[{}]},"_embedded":{"nice.indev:panel":[{"_links":{"self":[{}]},"_embedded":{"nice.indev:resource-list":{"_links":{"self":[{}]},"_embedded":{"nice.indev:resource":{"_links":{"self":[{}]},"_embedded":{"nice.indev:file":{"_links":{"self":[{"href":"/guidance/GID-TA10914/documents/html-content-3"}]},"ETag":null,"Id":"31a385b7-1956-45c3-8ad4-e3a3430b74d5","MimeType":"text/html","FileName":"HtmlContent","Length":0,"Hash":"0631457264FF7F8D5FB1EDC2C0211992A67C73E6","Name":"default","Reference":"GID-TA10914","ResourceTitleId":"html-content-3","ConsultationDocumentId":0}},"ETag":null,"Title":"Expected publication","Level":1,"PublishedDate":"2023-02-22T11:59:00","ExternalUrl":null,"ShowInDocList":true,"TextOnly":false,"ConsultationId":0,"ConsultationDocumentId":0,"IsCurrentViewableConsultationMarkup":false,"ConvertedDocument":false,"SupportsComments":false}},"ETag":null,"HasResources":true}},"ETag":null,"Title":"Expected publication","PanelType":"History","LegacyPanel":false,"OriginalReference":null,"UpdateReference":null,"ShowPanel":true},{"_links":{"self":[{}]},"_embedded":{"nice.indev:consultation":{"_links":{"self":[{"href":"/guidance/GID-TA10914/consultation/html-content-5"}]},"ETag":null,"Reference":"GID-TA10914","Title":"Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma when stem cell transplant is unsuitable  [ID4014]","ConsultationName":"Draft guidance: 1","StartDate":"2023-02-21T00:00:00","EndDate":"2023-03-14T17:00:00","ConsultationType":"Draft guidance","ResourceTitleId":"html-content-5","ProjectType":"TA","TechnologyType":"Medicine","ProductTypeName":"Technology appraisal guidance","ShowExpressionOfInterestSubmissionQuestion":false,"DevelopedAs":null,"RelevantTo":null,"ConsultationId":2095,"Process":"STA","HasDocumentsWhichAllowConsultationComments":true,"IsCHTE":true,"AllowedRole":"CHTETeam","FirstConvertedDocumentId":null,"FirstChapterSlugOfFirstConvertedDocument":null,"PartiallyUpdatedProjectReference":null,"OrigProjectReference":null,"AreasOfInterestList":[],"Hidden":false},"nice.indev:resource-list":{"_links":{"self":[{}]},"_embedded":{"nice.indev:resource":[{"_links":{"self":[{}]},"_embedded":{"nice.indev:file":{"_links":{"self":[{"href":"/guidance/GID-TA10914/consultation/html-content-5"},{"href":"/guidance/GID-TA10914/documents/html-content-5"}]},"ETag":null,"Id":"474c52d0-4423-4e0e-b998-76b2453fca56","MimeType":"text/html","FileName":"HtmlContent","Length":2256,"Hash":"05BD402CC493170FA22D3B9A38F106D9E984A055","Name":"default","Reference":"GID-TA10914","ResourceTitleId":"html-content-5","ConsultationDocumentId":0}},"ETag":null,"Title":"Draft guidance: 1","Level":1,"PublishedDate":"2023-02-22T11:59:00","ExternalUrl":null,"ShowInDocList":true,"TextOnly":false,"ConsultationId":2095,"ConsultationDocumentId":0,"IsCurrentViewableConsultationMarkup":true,"ConvertedDocument":false,"SupportsComments":false},{"_links":{"self":[{}]},"_embedded":{"nice.indev:file":{"_links":{"self":[{"href":"/guidance/GID-TA10914/documents/97"}]},"ETag":null,"Id":"b40432ca-d3e0-48b6-874e-77cced6b0219","MimeType":"application/vnd.openxmlformats-officedocument.wordprocessingml.document","FileName":"ID4014 daratumumab (len & dex)- MM (Untreat, transplant unsuitable)- draft guidance v1.0 to PM for Indev.docx","Length":63073,"Hash":"945081693991DD88EDE6EB9992C290D3BC706B1A","Name":"default","Reference":"GID-TA10914","ResourceTitleId":"97","ConsultationDocumentId":1}},"ETag":null,"Title":"Appraisal consultation document (online commenting)","Level":1,"PublishedDate":"2023-02-22T11:59:00","ExternalUrl":null,"ShowInDocList":true,"TextOnly":false,"ConsultationId":2095,"ConsultationDocumentId":1,"IsCurrentViewableConsultationMarkup":false,"ConvertedDocument":true,"SupportsComments":true},{"_links":{"self":[{}]},"_embedded":{"nice.indev:file":{"_links":{"self":[{"href":"/guidance/GID-TA10914/documents/129"}]},"ETag":null,"Id":"ce12826d-52c5-4237-8930-30942982b854","MimeType":"application/pdf","FileName":"ID4014 daratumumab (len & dex)- MM (Untreat, transplant unsuitable)- draft guidance v1.0 to PM.pdf","Length":344078,"Hash":"3ADE1913BAA53F399B802756EFA290F898E51398","Name":"default","Reference":"GID-TA10914","ResourceTitleId":"129","ConsultationDocumentId":0}},"ETag":null,"Title":"Appraisal consultation document  (PDF version)","Level":1,"PublishedDate":"2023-02-22T11:59:00","ExternalUrl":null,"ShowInDocList":true,"TextOnly":false,"ConsultationId":2095,"ConsultationDocumentId":0,"IsCurrentViewableConsultationMarkup":false,"ConvertedDocument":false,"SupportsComments":false},{"_links":{"self":[{}]},"_embedded":{"nice.indev:file":{"_links":{"self":[{"href":"/guidance/GID-TA10914/documents/committee-papers"}]},"ETag":null,"Id":"25d3a2f2-0f4d-4e21-ba55-c5c1709048c8","MimeType":"application/pdf","FileName":"[ID4014] daratumumab - Draft Guidance papers [redacted].pdf","Length":7899633,"Hash":"24324AAE5F9640D2F5094688B527CEAC340A6ECC","Name":"default","Reference":"GID-TA10914","ResourceTitleId":"committee-papers","ConsultationDocumentId":0}},"ETag":null,"Title":"Committee papers","Level":1,"PublishedDate":"2023-02-22T11:59:00","ExternalUrl":null,"ShowInDocList":true,"TextOnly":false,"ConsultationId":2095,"ConsultationDocumentId":0,"IsCurrentViewableConsultationMarkup":false,"ConvertedDocument":false,"SupportsComments":false},{"_links":{"self":[{}]},"_embedded":{"nice.indev:file":{"_links":{"self":[{"href":"/guidance/GID-TA10914/documents/1"}]},"ETag":null,"Id":"b62e3a10-ec2e-4767-88e3-22dc5f0020a8","MimeType":"application/pdf","FileName":"[ID4014] daratumuamb - Committee presentation [redacted].pdf","Length":1045903,"Hash":"DBCDBD2B4EA11C8D56C366F8BB62E0E430F6B9BE","Name":"default","Reference":"GID-TA10914","ResourceTitleId":"1","ConsultationDocumentId":0}},"ETag":null,"Title":"Public committee slides","Level":1,"PublishedDate":"2023-02-22T11:59:00","ExternalUrl":null,"ShowInDocList":true,"TextOnly":false,"ConsultationId":2095,"ConsultationDocumentId":0,"IsCurrentViewableConsultationMarkup":false,"ConvertedDocument":false,"SupportsComments":false}]},"ETag":null,"HasResources":true}},"ETag":null,"Title":"Draft guidance: 1","PanelType":"History","LegacyPanel":false,"OriginalReference":null,"UpdateReference":null,"ShowPanel":true},{"_links":{"self":[{}]},"_embedded":{"nice.indev:resource-list":{"_links":{"self":[{}]},"_embedded":{"nice.indev:resource":{"_links":{"self":[{}]},"_embedded":{"nice.indev:file":{"_links":{"self":[{"href":"/guidance/GID-TA10914/documents/committee-papers"}]},"ETag":null,"Id":"25d3a2f2-0f4d-4e21-ba55-c5c1709048c8","MimeType":"application/pdf","FileName":"[ID4014] daratumumab - Draft Guidance papers [redacted].pdf","Length":7899633,"Hash":"24324AAE5F9640D2F5094688B527CEAC340A6ECC","Name":"default","Reference":"GID-TA10914","ResourceTitleId":"committee-papers","ConsultationDocumentId":0}},"ETag":null,"Title":"Committee papers","Level":1,"PublishedDate":"2023-02-22T11:59:00","ExternalUrl":null,"ShowInDocList":true,"TextOnly":false,"ConsultationId":2095,"ConsultationDocumentId":0,"IsCurrentViewableConsultationMarkup":false,"ConvertedDocument":false,"SupportsComments":false}},"ETag":null,"HasResources":true}},"ETag":null,"Title":"Draft guidance: 1","PanelType":"Evidence","LegacyPanel":false,"OriginalReference":null,"UpdateReference":null,"ShowPanel":true},{"_links":{"self":[{}]},"_embedded":{"nice.indev:resource-list":{"_links":{"self":[{}]},"ETag":null,"HasResources":false}},"ETag":null,"Title":"Committee meetings","PanelType":"History","LegacyPanel":false,"OriginalReference":null,"UpdateReference":null,"ShowPanel":false},{"_links":{"self":[{}]},"_embedded":{"nice.indev:resource-list":{"_links":{"self":[{}]},"_embedded":{"nice.indev:resource":[{"_links":{"self":[{}]},"_embedded":{"nice.indev:file":{"_links":{"self":[{"href":"/guidance/GID-TA10914/documents/html-content-4"}]},"ETag":null,"Id":"d6e305ea-2903-4cd3-99eb-2b52b855369b","MimeType":"text/html","FileName":"HtmlContent","Length":0,"Hash":"0631457264FF7F8D5FB1EDC2C0211992A67C73E6","Name":"default","Reference":"GID-TA10914","ResourceTitleId":"html-content-4","ConsultationDocumentId":0}},"ETag":null,"Title":"Invitation to participate","Level":1,"PublishedDate":"2023-02-22T11:59:00","ExternalUrl":null,"ShowInDocList":true,"TextOnly":false,"ConsultationId":0,"ConsultationDocumentId":0,"IsCurrentViewableConsultationMarkup":false,"ConvertedDocument":false,"SupportsComments":false},{"_links":{"self":[{}]},"_embedded":{"nice.indev:file":{"_links":{"self":[{"href":"/guidance/GID-TA10914/documents/final-scope"}]},"ETag":null,"Id":"cd43190e-44e4-40f8-a9d5-3623270ff417","MimeType":"application/pdf","FileName":"ID4014 daratumumab (len & dex) MM final scope to PM for ITP [noACIC].pdf","Length":206702,"Hash":"1073586E778BDA67325E9AE6CC59B25E202A5226","Name":"default","Reference":"GID-TA10914","ResourceTitleId":"final-scope","ConsultationDocumentId":0}},"ETag":null,"Title":"Final scope","Level":1,"PublishedDate":"2022-03-25T12:17:00","ExternalUrl":null,"ShowInDocList":true,"TextOnly":false,"ConsultationId":0,"ConsultationDocumentId":0,"IsCurrentViewableConsultationMarkup":false,"ConvertedDocument":false,"SupportsComments":false},{"_links":{"self":[{}]},"_embedded":{"nice.indev:file":{"_links":{"self":[{"href":"/guidance/GID-TA10914/documents/final-matrix"}]},"ETag":null,"Id":"96c5df10-daca-4efe-af77-9600b10ccbd9","MimeType":"application/pdf","FileName":"ID4014 Daratumumab (with len dex) stakeholder list to PM - 100322 [noACIC].pdf","Length":192612,"Hash":"3F65B0F6E1F502EF502B5FE542C57B8CB13026D1","Name":"default","Reference":"GID-TA10914","ResourceTitleId":"final-matrix","ConsultationDocumentId":0}},"ETag":null,"Title":"Final stakeholder list","Level":1,"PublishedDate":"2022-03-25T12:17:00","ExternalUrl":null,"ShowInDocList":true,"TextOnly":false,"ConsultationId":0,"ConsultationDocumentId":0,"IsCurrentViewableConsultationMarkup":false,"ConvertedDocument":false,"SupportsComments":false},{"_links":{"self":[{}]},"_embedded":{"nice.indev:file":{"_links":{"self":[{"href":"/guidance/GID-TA10914/documents/scope-consultation-comments-and-responses"}]},"ETag":null,"Id":"ac9319fe-b0f8-4cdd-b382-625bbda007a4","MimeType":"application/pdf","FileName":"ID4014 daratumumab (with len dex) consultation response table to Pm for ITP (noACiC) AM.pdf","Length":199407,"Hash":"E72C7789F1C0E0DB040E04EB1290421953B1B88C","Name":"default","Reference":"GID-TA10914","ResourceTitleId":"scope-consultation-comments-and-responses","ConsultationDocumentId":0}},"ETag":null,"Title":"NICE's response to comments on the draft scope and provisional stakeholder list","Level":1,"PublishedDate":"2022-03-25T12:17:00","ExternalUrl":null,"ShowInDocList":true,"TextOnly":false,"ConsultationId":0,"ConsultationDocumentId":0,"IsCurrentViewableConsultationMarkup":false,"ConvertedDocument":false,"SupportsComments":false},{"_links":{"self":[{}]},"_embedded":{"nice.indev:file":{"_links":{"self":[{"href":"/guidance/GID-TA10914/documents/equality-impact-assessment-scoping"}]},"ETag":null,"Id":"5316de0f-4087-48f2-a323-aa963e055510","MimeType":"application/pdf","FileName":"ID4014 daratumumab (with len and dex) EIA form to AD for sign off - scoping [noACIC].pdf","Length":124856,"Hash":"26C19AA9520E9D5CF91502ACE469545C89803E34","Name":"default","Reference":"GID-TA10914","ResourceTitleId":"equality-impact-assessment-scoping","ConsultationDocumentId":0}},"ETag":null,"Title":"Equality impact assessment (Scoping)","Level":1,"PublishedDate":"2022-03-25T12:17:00","ExternalUrl":null,"ShowInDocList":true,"TextOnly":false,"ConsultationId":0,"ConsultationDocumentId":0,"IsCurrentViewableConsultationMarkup":false,"ConvertedDocument":false,"SupportsComments":false}]},"ETag":null,"HasResources":true}},"ETag":null,"Title":"Invitation to participate","PanelType":"History","LegacyPanel":false,"OriginalReference":null,"UpdateReference":null,"ShowPanel":true},{"_links":{"self":[{}]},"_embedded":{"nice.indev:resource-list":{"_links":{"self":[{}]},"_embedded":{"nice.indev:resource":[{"_links":{"self":[{}]},"_embedded":{"nice.indev:file":{"_links":{"self":[{"href":"/guidance/GID-TA10914/documents/html-content"}]},"ETag":null,"Id":"d4a4a298-b204-47ad-8749-6e998a63790c","MimeType":"text/html","FileName":"HtmlContent","Length":0,"Hash":"0631457264FF7F8D5FB1EDC2C0211992A67C73E6","Name":"default","Reference":"GID-TA10914","ResourceTitleId":"html-content","ConsultationDocumentId":0}},"ETag":null,"Title":"Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators","Level":1,"PublishedDate":"2022-03-11T20:55:00","ExternalUrl":null,"ShowInDocList":true,"TextOnly":false,"ConsultationId":1653,"ConsultationDocumentId":0,"IsCurrentViewableConsultationMarkup":false,"ConvertedDocument":false,"SupportsComments":false},{"_links":{"self":[{}]},"_embedded":{"nice.indev:file":{"_links":{"self":[{"href":"/guidance/GID-TA10914/documents/draft-scope-post-referral"}]},"ETag":null,"Id":"b2832e24-2702-4be3-ab6e-50d82f857144","MimeType":"application/pdf","FileName":"Appendix B - ID4014 daratumumab (len & dex) MM draft scope to PM [noACIC].pdf","Length":217478,"Hash":"33F6CA7C04A55B327B5411914A57B4CCB696F0C5","Name":"default","Reference":"GID-TA10914","ResourceTitleId":"draft-scope-post-referral","ConsultationDocumentId":0}},"ETag":null,"Title":"Draft scope post referral","Level":1,"PublishedDate":"2022-03-11T20:55:00","ExternalUrl":null,"ShowInDocList":true,"TextOnly":false,"ConsultationId":1653,"ConsultationDocumentId":0,"IsCurrentViewableConsultationMarkup":false,"ConvertedDocument":false,"SupportsComments":false},{"_links":{"self":[{}]},"_embedded":{"nice.indev:file":{"_links":{"self":[{"href":"/guidance/GID-TA10914/documents/draft-matrix-post-referral"}]},"ETag":null,"Id":"02a670ad-b1b4-4b1c-8ae7-4a5280d252ae","MimeType":"application/pdf","FileName":"Appendix C - ID4014 Daratumumab (with len dex) stakeholder list to PM - 170222 [noACIC].pdf","Length":194087,"Hash":"F926E12358D24FA557CB188599BE007CB680CE77","Name":"default","Reference":"GID-TA10914","ResourceTitleId":"draft-matrix-post-referral","ConsultationDocumentId":0}},"ETag":null,"Title":"Draft matrix post referral","Level":1,"PublishedDate":"2022-03-11T20:55:00","ExternalUrl":null,"ShowInDocList":true,"TextOnly":false,"ConsultationId":1653,"ConsultationDocumentId":0,"IsCurrentViewableConsultationMarkup":false,"ConvertedDocument":false,"SupportsComments":false}]},"ETag":null,"HasResources":true}},"ETag":null,"Title":"Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators","PanelType":"History","LegacyPanel":false,"OriginalReference":null,"UpdateReference":null,"ShowPanel":true}]},"ETag":null}},"ETag":"01000000-0000-0036-0000-000000000485","Summary":null,"Description":null,"ReferralDate":null,"SuspendDiscontinuedReason":null,"SuspendDiscontinuedUrl":null,"SuspendDiscontinuedUrlText":null,"LegacyModel":false,"ProductReference":null,"EvidenceAssessmentGroup":"Bristol Technology Assessment Group, University of Bristol","Reference":"GID-TA10914","ProjectType":"TA","TechnologyType":"Medicine","ProductTypeName":"Technology appraisal guidance","Process":"STA","Title":"Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma when stem cell transplant is unsuitable  [ID4014]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2023-08-23T00:00:00","LastModifiedDate":"2023-02-22T11:59:28.3363328","FirstGoLiveDate":"2021-11-26T00:02:57.2192866","CreatedDate":"2021-11-19T16:44:04.892398","DevelopedAs":null,"RelevantTo":null,"IdNumber":"4014","AreasOfInterestList":[],"TopicSelectionDecision":"Selected","TopicSelectionReason":null,"TopicSelectionDecisionDate":null,"TopicSelectionFurtherInfo":null,"IndicatorSubTypes":[]}